Skip to main content
. 2017 Sep 11;8:1695. doi: 10.3389/fmicb.2017.01695

FIGURE 6.

FIGURE 6

Protective effects of AR-13 in a mouse model of tularemia. (A) Survival curves of BALB/c mice infected by the I.N. route with 3 × 103 CFU of LVS followed by AR-13 treatment. The infected mice (4 or 5 mice/group) were given 2.5, 5, or 10 mg of AR-13/kg/day, starting about 1 h post-infection, once daily from day 0 for 10 days. A control PEG group was included. (B) Survival curves of BALB/c mice (5 mice/group) infected by the I.N. route with 10 CFU of F. tularensis SchuS4 followed by AR-13 treatment. Infected mice were given 2.5 mg AR-13/kg/day starting about 1 h post-infection, once daily from day 0 until day 4. (C) Survival curves of BALB/c mice (5 mice/group) infected I.N. with 10 CFU of F. tularensis SchuS4 followed by AR-13 treatment. The infected mice were given 5 mg AR-13/kg/day, starting about 1 h post-infection, with or without 0.25 mg gentamicin/kg/day given I.P.. AR-13 was given once daily from day 0 until day 4; gentamicin was given once daily from day 0 until the end of the experiment. A control PEG group was included (∗∗ difference with respect to PEG and 0.25 mg gentamicin control groups, p < 0.01).